Nacrez (Desogestrel)

Desogestrel binds to progesterone receptors, suppressing the luteinising hormone surge and thereby inhibiting ovulation. It also thickens cervical mucus and modifies the endometrial lining, creating conditions that reduce sperm penetration and implantation.

The specific dose and regimen are determined by the prescribing healthcare professional. In most cases, a single tablet is taken once daily at the same time each day, but the exact schedule should follow the prescriber’s instructions.

Nacrez is not intended for use during pregnancy; if pregnancy occurs, the product should be discontinued. Limited data are available for breastfeeding, and the decision to continue should be made by a healthcare provider after weighing potential risks and benefits.

To place an order, submit an enquiry on the Nacrez product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nacrez contains desogestrel, which offers a slightly longer half‑life and may provide more flexible missed‑dose windows compared with levonorgestrel‑based pills. Both classes are effective, but individual tolerability, side‑effect profiles and patient preference guide the choice of therapy.

Store Nacrez at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the package is tightly closed to maintain product stability.

Nacrez is taken orally as a tablet, usually once each day at the same time. It can be taken with or without food, but consistency in timing helps maintain effective hormone levels.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe allergic reactions, and liver dysfunction. Patients should seek immediate medical attention if they experience unexplained swelling, shortness of breath, severe rash, or jaundice.

Nacrez is contraindicated in women with known or suspected pregnancy, active or past thromboembolic disease, severe liver disease, uncontrolled hypertension, or known hypersensitivity to desogestrel or any tablet excipients.